

BRIM Biotechnology applies integrated and efficient translational science to develop new treatments that help combat and cure disease.

Our extensive experience and unique drug development engine, enables us to identify and incubate high-potential novel drug candidates and rapidly deliver partner-ready clinical assets.

We seek out the drug discoveries that have the highest potential to **defeat diseases, creating value for patients, partners, and investors.**

BRIM Biotechnology, Inc. (BRIM) is a rapidly growing biotechnology company that advances promising discoveries into disease-modifying treatments that transform patients' lives.

Founded and led by experienced global pharmaceutical experts, BRIM's expertise in translation science has delivered a rich and expanding pipeline of disease modifying treatments.

Our virtual business model, combined with our proprietary Pigment Epithelium-Derived Factor (PEDF) derived Short Peptide (PDSP) technology platform, means we bridge the gap between research and clinical development faster, de-risk the process, and have the flexibility to realise the potential of early-stage candidates in indications with high unmet medical needs.



Our pipeline currently consists of medicines for eye diseases and osteoarthritis. We develop therapies that not only treat the symptoms, but also have the potential to cure disease.



General Company Information

- Founded in August 2013.
- 16 employees located in Taiwan, 3 senior fellows in Taiwan, 5 senior fellows in the US.
- Licensed CN rights for lead candidate BRM421 to China Grand Pharm - USD 85~90M total deal size.
- Successful creation of spinout company Ascendo Biotechnology, Inc.



Leadership Team

Haishan Jang, PhD
 Co-Founder, Chief Executive Officer and BRIM Taiwan Chairwoman.
 Previously a member of Senior Management at Centocor. 30+ years' experience.

Frank Lee, PhD
 Co-Founder, Chief Strategy Officer and BRIM Cayman Chairman.
 Previously Vice President of DMPK at Takeda. 40+ years' experience.



Product Candidates Pipeline:

PRODUCT CANDIDATE	MOA	INDICATION	PHASE			
			PRECLINICAL	1	2	3
BRM 421	Regeneration	Dry Eye Syndrome	[Progress bar spanning Preclinical, Phase 1, and Phase 2]			
BRM 423	Regeneration	Severe Cornea Damage	[Progress bar spanning Preclinical and Phase 1]			
BRM 424	Regeneration	Neurotrophic Keratitis (Rare Disease)	[Progress bar spanning Preclinical and Phase 1]			
BRM 521	Regeneration	Osteoarthritis	[Progress bar spanning Preclinical]			

BRM 421

Our goal is to accelerate **BRM421** to commercialization. Subject to partnering, NDA filing is expected by 2026.

BRM 424

BRM424 orphan drug designation (ODD) candidate (same API and formulation as BRM421) expected to enter phase II clinical trials directly.

BRM 521

BRM521 is the 3rd indication of the same API as BRM421 and is one of a few new drug candidates that can show disease modification effects in osteoarthritis.

Development Milestones:


PRODUCT	PLATFORM	INDICATION	2020	2021	2022	2023	2024	2025	2026
BRM 421	PDSP (Peptide)	Dry Eye Syndrome	Phase 2/3	CMC			Pivotal Study		NDA
BRM 423	PDSP (Peptide)	Severe Cornea Damage				IND	Phase 2	Pivotal Study	
BRM 424	PDSP (Peptide)	Neurotrophic Keratitis (Rare Disease)		ODD	IND		Phase 2	Pivotal Study	
BRM 521	PDSP (Peptide)	Osteoarthritis	Discovery	Nonclinical/CMC			Phase 1		Phase 2



Leaders in Translational Science

- Our unique PDSP technology platform promotes the proliferation and differentiation of stem cells and then repair of damaged tissues.
- High potential, novel MoA can be applied across multiple therapy areas and indications.
- Our lead asset, BRM421, is on track to become a first-in-class treatment for dry eye syndrome (DES) which treats and repairs cornea damage.

Corporate Milestones:



BRIM Biotechnology is not limited by the traditional pharma R&D approach. Our efficient business model delivers maximum ROI.

2020
First Prize, Innovative Technology Award,
Taipei Biotech Awards.

2020
Outstanding Potential Award in Drug/Cell
Therapeutic Area, Taiwan BIO Awards.



2019
Outstanding Fundraising Award,
Taipei Prominent Enterprise Awards.

2018
Silver Prize for Drug Development,
from the Taiwan Ministry of Health and Welfare
and the Ministry of Economic Affairs.



To learn more about BRIM Biotechnology, Inc,
visit: www.brimbiotechnology.com or
[@brimbiotech](https://twitter.com/brimbiotech) [in](https://www.linkedin.com/company/brim-biotechnology) BRIM Biotechnology, Inc.

Address: 8F, No.1, Alley 30, Lane 358, Ruiguang Rd., Neihu Dist., Taipei 11492, Taiwan
Tel: +886-2-2659-8586 Fax: +886-2-2659-8779 Email: info@brimbiotech.com